Unicycive Therapeutics (UNCY) Price & Analysis

Compare

679 Followers

UNCY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.01 - $11.00

Previous CloseN/A

Volume1.16M

Average Volume (3M)662.40K

Market Cap

$52.22M

Enterprise Value$65.04M

Total Cash (Recent Filing)$19.77M

Total Debt (Recent Filing)$694.00K

Price to Earnings (P/E)―

Beta1.53

Next Earnings

Aug 18, 2025

EPS Estimate

-0.68

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding12,768,239

10 Day Avg. Volume299,794

30 Day Avg. Volume662,398

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.25

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.60

Forecast

1Y Price Target

$51.50

Price Target Upside1184.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Market PotentialConsidering the large market potential, a well-thought-out OLC commercial strategy, and committed funding from accredited investors, UNCY is attractive to a long-term investor.

Patient OutcomesThe P2 study of OLC demonstrated strong patient-reported outcomes, reducing pill burden by 50%, improving adherence, and achieving higher satisfaction compared to prior phosphate binders.

Regulatory ApprovalNo concerns with the drug’s safety or efficacy, leading to a positive outlook on OLC eventually receiving approval for the treatment of hyperphosphatemia following a delay.

Bears Say

Manufacturing IssuesThe FDA has identified a cGMP compliance-related deficiency with the company’s third-party manufacturing vendor.

Regulatory DelaysManagement plans to seek a Type A meeting with the FDA due to issues raised in the CRL, which relate solely to a failed cGMP inspection.

Unicycive Therapeutics News

Unicycive Therapeutics announces publication of OLC trial data

Unicycive Therapeutics (UNCY) announced the publication of trial data describing the safety and tolerability of oxylanthanum carbonate, OLC,...

20d ago

UNCY

Unicycive Regains Nasdaq Compliance After Stock Split

Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. On July 8, 2025, Unicycive Therapeutics announced it regained...

1M ago

UNCY

Unicycive Therapeutics regains compliance with Nasdaq bid price requirement

Unicycive Therapeutics (UNCY) has regained compliance with Nasdaq continued listing standard for minimum share price. On July 7,...

1M ago

UNCY

Unicycive Therapeutics approval delay ‘not a surprise,’ says Noble Capital

The receipt of a Complete Response Letter in response to Unicycive’s New Drug Application for Oxylanthanum Carbonate was...

1M ago

UNCY

Unicycive Receives FDA CRL for New Drug Application

An update from Unicycive Therapeutics ( ($UNCY) ) is now available. On June 30, 2025, Unicycive Therapeutics announced...

1M ago

UNCY

H.C. Wainwright keeps Buy on Unicycive Therapeutics , says CRL ‘anticipated’

H.C. Wainwright analyst Swayampakula Ramakanth notes that Unicycive has announced the receipt of a complete response letter from...

1M ago

UNCY

Buy Rating for Unicycive Therapeutics Amid Regulatory and Financial Optimism

Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report) and...

1M ago

UNCY

Unicycive receives CRL for oxylanthanum carbonate NDA for hyperphosphatemia

Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration has issued a CRL for its New...

1M ago

UNCY

Unicycive Therapeutics sees cash runway into 2H26

Unicycive currently has an unaudited cash balance of approximately $20.7M, with cash runway currently expected into the second...

1M ago

UNCY

Unicycive Therapeutics Executes Reverse Stock Split

Unicycive Therapeutics ( ($UNCY) ) has issued an update. On June 9, 2025, Unicycive Therapeutics‘ stockholders approved a...

2M ago

UNCY

Unicycive Therapeutics Inc trading halted, news pending

19:50 EDT Unicycive Therapeutics (UNCY) Inc trading halted, news pending Published first on TheFly – the ultimate source...

2M ago

UNCY

Unicycive Therapeutics announces 1-for-10 reverse stock split

Unicycive Therapeutics (UNCY) announced that it will implement a 1-for-10 reverse split of the issued shares of its...

2M ago

UNCY

Why Is Unicycive Therapeutics Stock (UNCY) Down 35% Today?

Unicycive Therapeutics stock sank on Tuesday after the company announced a setback from the FDA. ...

2M ago

UNCY

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories

It’s time to dive into the biggest stock market stories that traders need to know about on Tuesday. ...

2M ago

BTC

UNCY FAQ

What was Unicycive Therapeutics’s price range in the past 12 months?

Unicycive Therapeutics lowest stock price was $2.01 and its highest was $11.00 in the past 12 months.

What is Unicycive Therapeutics’s market cap?

Unicycive Therapeutics’s market cap is $52.22M.

When is Unicycive Therapeutics’s upcoming earnings report date?

Unicycive Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 5 days.

How were Unicycive Therapeutics’s earnings last quarter?

Unicycive Therapeutics released its earnings results on May 14, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.

Is Unicycive Therapeutics overvalued?

According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unicycive Therapeutics pay dividends?

Unicycive Therapeutics does not currently pay dividends.

What is Unicycive Therapeutics’s EPS estimate?

Unicycive Therapeutics’s EPS estimate is -0.68.

How many shares outstanding does Unicycive Therapeutics have?

Unicycive Therapeutics has 12,768,239 shares outstanding.

What happened to Unicycive Therapeutics’s price movement after its last earnings report?

Unicycive Therapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.921%.

Which hedge fund is a major shareholder of Unicycive Therapeutics?

Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 0.

Unicycive Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-2355.27%

Trailing 12-Months

Asset Growth

-46.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Unicycive Therapeutics

Unicycive Therapeutics (UNCY) is a biopharmaceutical company focused on developing novel treatments for kidney diseases. The company operates within the healthcare sector, specifically targeting nephrology. Its core products include innovative therapies aimed at addressing unmet medical needs in patients suffering from chronic kidney diseases and related conditions.

Unicycive Therapeutics (UNCY) Earnings & Revenues

Historic Earnings Reports

UNCY Stock 12 Month Forecast

Average Price Target

$51.50

▲(1184.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","121":"$121","31.75":"$31.8","61.5":"$61.5","91.25":"$91.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,31.75,61.5,91.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,13.753846153846153,22.607692307692304,31.46153846153846,40.31538461538461,49.16923076923076,58.023076923076914,66.87692307692308,75.73076923076923,84.58461538461538,93.43846153846152,102.29230769230769,111.14615384615384,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,8.484615384615385,12.06923076923077,15.653846153846155,19.23846153846154,22.823076923076925,26.407692307692308,29.99230769230769,33.57692307692308,37.16153846153846,40.746153846153845,44.33076923076923,47.91538461538462,{"y":51.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.9,5.2153846153846155,5.530769230769231,5.846153846153847,6.161538461538462,6.476923076923077,6.792307692307693,7.107692307692308,7.423076923076923,7.7384615384615385,8.053846153846154,8.36923076923077,8.684615384615384,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >